Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
This research aims to evaluate the use of Direct Selective Laser Trabeculoplasty DSLT in adults newly diagnosed with primary open-angle glaucoma or similar conditions such as ocular hypertension. The study focuses on untreated patients to understand how well DSLT reduces intraocular pressure IOP without requiring medications. It addresses the current need for alternatives to medications, which can be difficult to use due to side effects and adherence challenges. Participants will receive the DSLT procedure, which involves delivering 120 laser shots at the eyes limbus over 2.4 seconds to help control aqueous fluid outflow and lower IOP. The study measures the reduction in IOP at 1, 3, and 6 months, with the primary goal of achieving more than a 20% decrease without medications. Only patients with baseline IOPs above 21 mmHg and no prior glaucoma treatments will be included. During the study, participants will undergo regular eye pressure assessments to track treatment effects and determine the need for additional interventions. Researchers will monitor the percentage of eyes reaching the target IOP reduction and record any secondary treatments required. The total follow-up period for assessing outcomes is 6 months, ensuring a clear understanding of DSLTs impact on early-stage glaucoma management.
Actively Recruiting
Healthy Volunteer
This research evaluates different types of intraocular lens IOL implantations in adults with cataracts aged 40 years and older. It is a prospective, randomized, multicenter study with two stages an initial enrollment period with three groups, followed by a refined head-to-head comparison based on initial results. The study focuses on comparing bilateral Clareon PanOptix, bilateral Clareon PanOptix Pro, and a mixed implantation of Clareon PanOptix Pro and Clareon Vivity lenses. Participants receive one of three types of IOL implantations during cataract surgery bilateral Clareon PanOptix, bilateral Clareon PanOptix Pro, or a mix of Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye. The study proceeds in two stages, beginning with an initial three-arm enrollment followed by a focused comparison in the second stage based on Stage 1 data. Treatments are implanted during routine cataract surgery. Throughout the study, participants attend scheduled visits to assess visual outcomes and complete questionnaires about their vision and lens satisfaction. Researchers measure corrected distance visual acuity and other vision parameters at three months after surgery, including intermediate and near visual acuities, contrast sensitivity under different lighting conditions, refractive outcomes, pupil size, and patient-reported visual disturbances and satisfaction. The study lasts until April 2027, with monitoring focused on post-operative visual performance.
Actively Recruiting
This research aims to learn about the safety and effects of a medicine called ritlecitinib for treating moderate alopecia areata AA, a condition causing patchy hair loss. The study includes participants aged 12 years and older who have had patchy hair loss for at least 6 months but not more than 10 years, without other causes of hair loss. It is a phase 3 randomized, double-blind, placebo-controlled trial designed to evaluate ritlecitinib in adolescents and adults with AA. Participants will be randomly assigned to receive either ritlecitinib 50 mg or placebo once daily by mouth for 24 weeks. After this, depending on their response, their treatment may remain the same or change to either 50 mg or 100 mg ritlecitinib for another 23 weeks. Those receiving placebo initially may also be switched to ritlecitinib during this second period. Treatments are taken at home, and the study includes multiple groups based on response to treatment. Participants will be involved for about 57 weeks, including study visits at the clinic and some phone check-ins. Researchers will monitor hair loss using the Severity of Alopecia Tool SALT and other assessments like eyebrow and eyelash evaluations, patient satisfaction, and emotional impact. Safety will be closely monitored through adverse event tracking and laboratory tests. A follow-up visit about 4 weeks after the last dose will check on participants health.
Actively Recruiting
Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR448851, an oral medication taken once daily, in people with early Alzheimers disease, including mild cognitive impairment due to Alzheimers and mild Alzheimers dementia. This Phase 2 randomized, placebo-controlled study focuses on participants aged 55 to 85 years who have evidence of cerebral amyloid pathology. The study aims to measure changes in plasma biomarkers and monitor safety outcomes over time. Participants are randomly assigned to receive either SAR448851 at one of two doses or a placebo, taken orally once daily for 48 weeks during Part A. Those who complete Part A can join an open-label extension in Part B. The total study duration may last up to 111 weeks for Parts A and B, or up to 63 weeks for the optional dose 2 cohort. Various assessments, including brain imaging and fluid biomarker measurements, will be used to evaluate treatment effects. Throughout the trial, participants will have regular evaluations including brain MRIs to monitor for adverse events such as ARIA-E and ARIA-H, laboratory tests, vital sign checks, ECGs, and cognitive assessments. Researchers will track changes in Alzheimers disease biomarkers from baseline through Week 96. Safety and tolerability will be continuously assessed, and participants cognitive status will be monitored to understand the treatments impact over time.
Actively Recruiting
Evaluation of TSND-201 Capsules Versus Placebo for Treating Post Traumatic Stress Disorder in Adults
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.
1-10 of 17
1